NCT05504772 Precision Medicine for Every Child With Cancer
| NCT ID | NCT05504772 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Australian & New Zealand Children's Haematology/Oncology Group |
| Condition | Childhood Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,500 participants |
| Start Date | 2022-12-16 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,500 participants in total. It began in 2022-12-16 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To improve outcomes for childhood cancer patients through the implementation of precision medicine.
Eligibility Criteria
Inclusion Criteria: 1. Age \< 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate. 2. Life expectancy \>6 weeks at time of enrolment 3. Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged \<18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.
Contact & Investigator
David Ziegler
PRINCIPAL INVESTIGATOR
SCHN
Frequently Asked Questions
Who can join the NCT05504772 clinical trial?
This trial is open to participants of all sexes, aged 0 Years or older, up to 25 Years, studying Childhood Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05504772 currently recruiting?
Yes, NCT05504772 is actively recruiting participants. Contact the research team at SCHN-ZERO2@health.nsw.gov.au for enrollment information.
Where is the NCT05504772 trial being conducted?
This trial is being conducted at Adelaide, Australia, Brisbane, Australia, Hobart, Australia, Melbourne, Australia and 7 additional locations.
Who is sponsoring the NCT05504772 clinical trial?
NCT05504772 is sponsored by Australian & New Zealand Children's Haematology/Oncology Group. The principal investigator is David Ziegler at SCHN. The trial plans to enroll 3,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.